AstraZeneca to Invest $1B for the Transformation of Healthcare in China

Shots:

• AstraZeneca takes three large-scale initiatives which include the formation of new Global R&D Centre and an AI Innovation Centre, both in Shanghai and collaborate with CICC to jointly formed the Healthcare Industrial Fund for the transformation of healthcare in China
• Initially, AstraZeneca funded $1B to the Health Care Fund supporting the domestic companies, the R&D Centre to focus on the disease prevalent in China and AI innovation Centre is to utilize digital technology in R&D, manufacturing, operations and commercialization to accelerate the delivery of therapies in China and across the globe
• AstraZeneca signed MoU with the Shanghai Jing’an District People’s Government at the CIIE for the creation of R&D and AI Centres and a separate agreement with CICC for the joint investment fund. Additionally, AstraZeneca signed a license agreement with Sun Pharma for novel ready-to-use (RTU) infusion oncology therapies in China

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: DW.com